Document is current
Any future updates will be listed below
-
Authors
Azar, Alexander E. https://orcid.org/0009-0000-8037-6953
Shukla, Priya
Allan, Kevin C.
Singh, Rishi P.
Talcott, Katherine E. https://orcid.org/0000-0003-0458-4181
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR002548, UL1TR002548)
Research to Prevent Blindness (P30EY025585(BA-A), P30EY025585(BA-A))
- License Information
-
More Information
Article History
Received: 5 March 2025
Revised: 12 September 2025
Accepted: 23 September 2025
First Online: 4 October 2025
Competing interests
: RPS reports personal fees from Apellis, Iveric Bio, Eyepoint, Regenxbio, Genentech, Bausch and Lomb, Zeiss, Alcon, and Regeneron, and research grants from Jannsen. KET: Alimera (consultant), Apellis (consultant), Bausch and Lomb (consultant), Eyepoint (consultant), Genentech (consultant, speaker’s bureau), Iveric Bio (speaker’s bureau), Regeneron (research), Regenxbio (research), Zeiss (research). The remaining authors have no financial disclosures.
